Peptide CDMO Consolidation Accelerates: Samsung Biologics Launches Formal Tender for PolyPeptide as CordenPharma Closes AmbioPharm Deal

Key takeaways

• Samsung Biologics published its formal tender offer prospectus for PolyPeptide Group on 31 August 2026, valuing the Swiss peptide CDMO at approximately CHF 1.46 billion (roughly USD 1.8 billion) and carrying a 40 per cent premium to the pre-speculation share price.
• The main acceptance period is expected to run from 15 September to 12 October 2026, subject to a mandatory ten-day cooling-off period on the SIX Swiss Exchange beginning 1 September 2026.
• CordenPharma separately completed its acquisition of US-headquartered AmbioPharm on 3 August 2026, adding facilities in South Carolina and Shanghai to its global peptide network.
• Both transactions reflect the same underlying driver: commercial-scale solid-phase peptide synthesis capacity, the primary input for GLP-1 active pharmaceutical ingredients, cannot be constructed on a short timeline, making existing assets the fastest route to supply.
• Announced peptide CDMO investments crossed USD 2.4 billion year-to-date in 2026, according to industry tracking data, yet lead times for large-scale SPPS capacity additions remain 18–36 months.

The Samsung Biologics / PolyPeptide transaction

Samsung Biologics, operating through its newly created Swiss subsidiary Samsung Peptide AG, published the formal offer prospectus for PolyPeptide Group AG (SIX: PPGN) on 31 August 2026. The all-cash offer of CHF 44.31 per share implies an aggregate equity value of approximately CHF 1.46 billion. The offer price represents a 40 per cent premium to PolyPeptide's unaffected share price on 10 April 2026, the last trading day before media speculation about a potential acquisition first emerged.

Transaction support is strong at the outset. PolyPeptide's board of directors unanimously recommended that shareholders accept the offer, and the company's largest shareholder — holding approximately 55.65 per cent of shares outstanding — has committed irrevocably to tender its entire stake. The offer therefore already commands effective majority support, though Swiss takeover law requires a minimum acceptance threshold of 66⅔ per cent on a fully diluted basis before the transaction can close.

Under Swiss procedure, the offer may not be accepted before the expiration of a ten-day cooling-off period on the SIX Swiss Exchange, which began on 1 September 2026. The main offer period is expected to run from 15 September to 12 October 2026, with closing targeted towards the end of 2026, subject to regulatory approvals. Once complete, Samsung Biologics plans to delist PolyPeptide from the SIX.

What PolyPeptide brings

PolyPeptide is one of a small number of CDMOs with validated, commercial-scale solid-phase peptide synthesis infrastructure. The company's large-scale SPPS facility in Braine-l'Alleud, Belgium — a €100 million investment described as the largest single investment in PolyPeptide's 70-year history — has operated at target utilisation since early 2026. That site is understood to serve a long-term commercial agreement expected to generate approximately €100 million in annual orders at full ramp. PolyPeptide's Phase III development pipeline had expanded to 37 projects by mid-2026, and the company reported preliminary H1 2026 revenues growing 41.6 per cent to EUR 236.6 million, with an EBITDA margin of 20.7 per cent.

For Samsung Biologics, the acquisition broadens the scope of its existing offerings beyond antibody drugs and antibody-drug conjugates into peptide therapeutics, which analysts regard as one of the fastest-growing segments of the biopharmaceutical industry. Industry commentary characterises the deal as Korea's largest-ever biopharma transaction and a direct bet on GLP-1 peptide API capacity, which cannot be built greenfield on a short timeline.

The CordenPharma / AmbioPharm closure

Separately, CordenPharma completed its acquisition of AmbioPharm on 3 August 2026, integrating the US-headquartered peptide CDMO's two sites into its global network. AmbioPharm operates facilities in North Augusta, South Carolina, and Shanghai, China, employing approximately 400 people across both locations.

The North Augusta site, now rebranded CordenPharma South Carolina, adds significant purification and lyophilisation capacity for peptide APIs and will complement CordenPharma's existing Colorado facility to allow fully US-based supply chains for large-scale commercial peptide projects. The Shanghai campus, now CordenPharma Shanghai, adds upstream peptide manufacturing capacity across solid-phase, liquid-phase, and hybrid synthesis routes, providing clinical and commercial supply options for global customers.

CordenPharma, a portfolio company of private equity group Astorg since 2022, has used the acquisition to expand its network to more than 13 facilities across Europe, North America, and Asia, with a combined workforce of approximately 3,500. Financial terms of the CordenPharma/AmbioPharm deal were not disclosed publicly.

The structural driver: GLP-1 manufacturing bottlenecks

Both transactions are intelligible against the same backdrop. Peptide CDMO announced investments crossed USD 2.4 billion year-to-date in 2026, driven by GLP-1 demand and a broadening pipeline of therapeutic peptides, yet lead times for large-scale SPPS capacity remain 18–36 months, creating a near-term supply bottleneck even as capital commitments are significant.

Peptide manufacturing requires specialised technology — principally solid-phase or liquid-phase peptide synthesis, followed by large-scale reverse-phase HPLC purification — and substantial capital investment. Purification of peptide APIs via preparative HPLC is a recognised bottleneck at commercial scale, requiring columns and solvent handling infrastructure that themselves carry extended procurement lead times.

The recognition that excessive concentration of peptide API supply in Asia-Pacific creates unacceptable supply chain risk has pushed North American and European pharmaceutical sponsors to seek geographically diversified CDMO partnerships. Both the Samsung/PolyPeptide and CordenPharma/AmbioPharm transactions add capacity in multiple jurisdictions simultaneously, reflecting this strategic diversification logic.

The global peptide CDMO market is forecast to reach USD 29.12 billion by 2035, underpinned by GLP-1 commercial volumes and a widening pipeline of therapeutic peptides beyond metabolic medicine. Market access and comparability studies represent key complexity factors: moving peptide processes between manufacturing sites requires extensive analytical bridging and impurity-profile alignment, increasing transfer timelines and regulatory risk. That complexity reinforces the value of acquiring established, validated sites rather than building new ones.

Implications for research procurement

For UK research organisations sourcing peptide reference standards and GMP intermediates, the consolidation of the CDMO sector has several near-term implications.

Supplier concentration. As the field narrows towards a smaller number of large integrated CDMOs, procurement teams should monitor whether contract terms, minimum order quantities, and technical service models change post-integration. Relationship continuity with technical contacts at acquired entities should not be assumed.

Supply chain geography. Both deals add or preserve manufacturing nodes outside Asia, which may improve supply chain resilience for organisations with regulatory or procurement preferences for European or US-sourced material.

Technology transfer risk. Where research-grade supply agreements depend on manufacturing sites being integrated into new parent organisations, procurement teams should seek clarification on any planned process or site changes and request updated certificates of analysis that document continuity of impurity profiles and purity specifications.

Tender timeline. The Samsung Biologics offer for PolyPeptide remains open and is subject to regulatory review. Procurement teams with active or planned supplier agreements with PolyPeptide should note that ownership change is not expected before the end of 2026 and should request communication from PolyPeptide on any operational continuity commitments made as part of the transaction agreement.